Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:38:28.925Z.
Consensus retrieved: 2026-10-06T16:18:32.234Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:38:28.925Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77ffd79d43f0055242b38282a97f53e69ef3ec7586b4a3f7de15a7f16befe37a
Forward PE Ratio (N/A) = Dated Quote Price ($24.78) / Consensus Forward EPS ($-2.50)
FORWARD PE RATIO
N/A
SpyGlass Pharma, Inc. Common Stock
Market Cap
$828.48M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $828.48M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 10.79 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 13.44 |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $24.78, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.50 | $-2.52 – $-2.47 | 3 | n/m |
| 2027-12-31 | $-2.81 | $-3.08 – $-2.56 | 4 | n/m |
| 2028-12-31 | $-3.06 | $-3.76 – $-2.64 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
